drugset
drugset / Trial / NCT04838080

Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo

NCT04838080 ↗

Phase 1 Unknown 38 enrolled Kocak Farma
RandomizedParallel-groupDouble-blindPrevention

Summary

The objective of this study is to determine the safety and immunogenicity of two different strengths (4 µg and 6 µg) of an inactivated COVID-19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19

Timeline

Start
2021-03-19
Primary completion
2021-06-01
Completion
2021-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Vaccine 4 ug Intramuscular
Subject Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Vaccine 6 ug Intramuscular

Indications

No indication recorded.